<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156495">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02029092</url>
  </required_header>
  <id_info>
    <org_study_id>G1302</org_study_id>
    <nct_id>NCT02029092</nct_id>
  </id_info>
  <brief_title>BIOFLOW III Satellite-ELADIS</brief_title>
  <official_title>BIOTRONIK- Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice III- ELADIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C.E.M. Biotronik, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C.E.M. Biotronik, S.A.</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal
      Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to
      long-term complications range from rather immediate elastic coil or vessel contraction to
      longer processes like smooth muscle cell proliferation and excessive production of extra
      cellular matrix, thrombus formation and atherosclerotic changes like restenosis or
      angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30 to
      50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents (BMS),
      designed to address the limitations of PTCA, reduced the angiographic and clinical
      restenosis rates in De Novo lesions compared to PTCA alone and decreased the need for CABG.
      BMS substantially reduced the incidence of abrupt artery closure, but restenosis still
      occurred in about 20 to 40% of cases, necessitating repeat procedures.

      The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by
      adding an antiproliferative drug (directly immobilized on the stent surface or released from
      a polymer matrix), which inhibits neontimal hyperplasia. The introduction of DES greatly
      reduced the incidence of restenosis and resulted in better safety profile as compared to BMS
      with systemic drug administration. These advantages and a lower cost compared to surgical
      interventions has made DES an attractive option to treat coronary artery disease.

      Therefore this observational registry has been designed for the clinical evaluation of the
      ORSIRO LESS requiring coronary revascularization with DES. Results will contribute to the
      collection of clinical evidence for the clinical performance and safety of ORSIRO drug
      eluting stent system in daily clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure  (TLF)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite of cardiac death, target vessel Q-wave or non Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG) and clinically driven Target Lesion Revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLF</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis rate</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>up to discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation, without using any adjunctive device outside the assigned treatment strategy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>up to 7 days after procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation, without using any adjunctive device and without the occurrence of ischemia-driven major cardiac event during the hospital stay to a maximum of the first seven days post index procedure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic coronary artery disease

          -  Subject has signed informed consent for data release

          -  Subject is geographically stable and willing to participate at all follow up
             assessments

          -  Subject is≥18 years of age.

        Exclusion Criteria:

          -  Subject did not sign informed consent for data release

          -  Pregnancy

          -  Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other
             anticoagulation, antiplatelet therapy required for PCI, stainless steel, Sirolimus or
             contrast media.

          -  Planned surgery within 6 months after PCI unless dual antiplatelet therapy will be
             maintained

          -  Currently participating in another study and primary endpoint is not yet reached.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leticia Mora, Lead Field Clinical Research E</last_name>
    <phone>+34 636 175 335</phone>
    <email>leticia.mora@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonia Martin, Clincal Manager</last_name>
    <phone>+34 649 845298</phone>
    <email>sonia.martin@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario León</name>
      <address>
        <city>León</city>
        <state>A/Altos de Nava s/n</state>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Estevez Loureiro, Dr</last_name>
      <phone>+34987237683</phone>
    </contact>
    <investigator>
      <last_name>Rodrigo Estevez Loureiro, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armando Pérez de Prado, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Armando Pérez de Prado, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Virgen de la Arrixaca</name>
      <address>
        <city>Morcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Valdes, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Mariano Valdes, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo de Hospitalario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramiro Trillo, Dr</last_name>
      <phone>+34981950000</phone>
      <email>ramirotrillo@mac.com</email>
    </contact>
    <investigator>
      <last_name>Ramiro Trillo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Txagorritxu</name>
      <address>
        <city>Vitoria-Gasteiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Torres, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Alfonso Torres, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Vizcaya</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Fernandez, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Luis Fernandez, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>International</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Observational registry</keyword>
  <keyword>Orsiro Drug Eluting Stent (DES)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Treatment of coronary artery disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Angina</keyword>
  <keyword>Acute Myocardial Infarction (AMI)</keyword>
  <keyword>Small Vessels</keyword>
  <keyword>Chronical Total Occlusion (CTO)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
